Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA

Rank in Stocks #20873
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Share Price
$3.27
Last synced: 2026-11-12
Market Cap
$76.71M
Change (1 day)
1.87%
Change (1 year)
-44.10%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Coya Therapeutics, Inc. (COYA)
Operating Margin as of November 2026 TTM: -675.34%
According to Coya Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -675.34%. At the end of 2025 the company had an operating margin of -255.05%.
Operating Margin history for Coya Therapeutics, Inc. from 2020 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -675.34% 164.79%
2025 -255.05% -47.45%
2024 -485.35% 268.61%
2023 -131.67% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -99.71%
US
33.87% -100.05%
US
-116.04% -99.83%
US
25.57% -100.04%
AU
31.23% -100.05%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Coya Therapeutics, Inc.'s operating margin

What is Coya Therapeutics, Inc.'s operating margin?

Coya Therapeutics, Inc.'s operating margin is -675.34%, as of Nov 2026.

What was Coya Therapeutics, Inc.'s operating margin in 2025?

In 2025, Coya Therapeutics, Inc.'s operating margin was -255.05%, compared with -485.35% in 2024.

How has Coya Therapeutics, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Coya Therapeutics, Inc.'s operating margin was highest in 2022 (0.00%) and lowest in 2024 (-485.35%).

How does Coya Therapeutics, Inc.'s operating margin compare with similar companies?

Coya Therapeutics, Inc.'s operating margin (-675.34%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.